U.S. Firm Set To Sue S. Korea Dog Cloner Tied To Disgraced Scientist
This article was originally published in PharmAsia News
A U.S. company is reported set to file suit in South Korea, charging a patent violation involving the country's disgraced South Korean cloning scientist. Start Licensing, which holds a license from the U.K.'s Roslin Institute, famous for cloning Dolly the sheep, has hired a South Korean patent lawyer to sue RNL Bio of South Korea, a commercial dog-cloning company. Start says it licensed commercial rights for the Roslin technology to BioArts, which in turn relies on the work of Hwang Woo-suk, infamous South Korean stem cell cloner. A former Hwang collaborator provides cloning technology to RNL, completing the circle of involvement and alleged conflict. (Click here for more
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.